SavedAdd your journal

Journals / Zeynep Kamil medical journal (Online) / 2021 / Cilt: 52 - Sayı: 2

nvestigation of plasminogen activator inhibitor-1 4G/5G gen polymorphism in Turkish preeclamptic patients

Ebru ÇÖĞENDEZ
Önder TOSUN
Mahmut ERDEMOĞLU
Pages
61–66
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: According to the results obtained from present study, we think that PAI1 gene polymorphism does not contribute to individual differences for the sensitivity of preeclampsia development.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The plasminogen activator inhibitor type-1 (PAI-1) is a genetic risk factor that plays a role in the pathogenesis of pre-eclampsia and elevated levels of PAI-1 may lead to an increased risk of thrombosis.
📊
Key Findings & Data:At preent, there is considerable controversy about the association between PAI-1 gene polymorphism and preeclampsia.
💡
Conclusion & Impact:Conclusion: According to the results obtained from present study, we think that PAI1 gene polymorphism does not contribute to individual differences for the sensitivity of preeclampsia development.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The plasminogen activator inhibitor type-1 (PAI-1) is a genetic risk factor that plays a role in the pathogenesis of pre-eclampsia and elevated levels of PAI-1 may lead to an increased risk of thrombosis. At preent, there is considerable controversy about the association between PAI-1 gene polymorphism and preeclampsia. The aim of this study is to investigate whether the pattern of PAI-1 gene polymorphism is a useful marker for preeclampsia or not. Material and Methods: Our study included 83 hypertensive pregnant women (64 preeclamptic women, 12 pregnant women with HELLP syndrome, and 7 eclamptic women) genotyped for PAI-1 gene polymorphism (4G/4G, 4G/5G, and 5G/5G) and 20 healthy pregnant women. The Chi-square analysis was used to evaluate the differences in genotype and allele frequencies between hypertensive pregnant women and healthy controls. Results: The highest PAI-1 gene polymorphism rate was found in the hypertensive group and healthy controls in the 4G/5G allele distribution. No significant difference was determined between the hypertensive group and healthy controls regarding the distribution of PAI-1 4G/4G, 4G/5G, and 5G/5G polymorphic alleles. Conclusion: According to the results obtained from present study, we think that PAI1 gene polymorphism does not contribute to individual differences for the sensitivity of preeclampsia development. However, prospective cohort studies with larger sample sizes are needed to clearly demonstrate the contribution of PAI-1 gene polymorphism to serious pregnancy complications such as preeclampsia.

🔖

Cite This Article

ÇÖĞENDEZ, E., TOSUN, Ö., ERDEMOĞLU, M. (2022). nvestigation of plasminogen activator inhibitor-1 4G/5G gen polymorphism in Turkish preeclamptic patients. Zeynep Kamil medical journal (Online), Cilt: 52 - Sayı: 2, 61–66. https://ajindex.com/articles/426170

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 1997;11(2):72–9
  2. Chappell LC, Seed PT, Briley A, Hunt BJ, Charnock-Jones DS, Kelly FJ, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002;187(1):127–36
  3. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990;23(3):197–211
  4. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994;101(6):488–92
  5. Kluft C, Jie AF, Sprengers ED, Verheijen JH. Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Lett 1985;190(2):315–8
  6. Jørgensen M, Philips M, Thorsen S, Selmer J, Zeuthen J. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma. Thromb Haemost 1987;58(3):872–8
  7. Ye Y, Vattai A, Zhang X, Zhu J, Thaler CJ, Mahner S, et al. Role of plasminogen activator ınhibitor type 1 in pathologies of female reproductive diseases. Int J Mol Sci 2017;18(8):1651–68
  8. Said JM, Tsui R, Borg AJ, Higgins JR, Moses EK, Walker SP, et al. The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women. J Thromb Haemost 2012;10(5):881–6
  9. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005;93(4):631–40
  10. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77(1):67–75
  11. Ditisheim A, Sibai BM. Diagnosis and management of HELLP syndrome complicated by liver hematoma. Clin Obstet Gynecol 2017;60(1):190–7
  12. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357(9249):53–6
  13. Williams PJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25(4):405–17
  14. De Boer K, Lecander I, ten Cate J, Borm JJ, Treffers PE. Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988;158(3 Pt 1):518–22
  15. Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 2002;126(11):1401–4
  16. Banfi